April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
The FDA issued 14 oncology approvals this quarter, including the first tumor-infiltrating lymphocyte therapy.
A few important details to help attendees get the most out of their experience at the AACR Annual Meeting...
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
Three patients share their experiences about having Lynch syndrome.
Event cochair Dr. Michael Caligiuri shares how attendees can form connections to take science from bench to market.
Lobular breast cancer accounts for 15% of all breast cancer cases, but it is understudied.
February’s selections include a modified Zika virus to treat cancer, insights into treatment resistance, and more.
January’s selections include disparities in genetic testing, updates from a breast cancer clinical trial, and more.
This quarter’s new tools and strategies for cancer research included molecular jackhammers and biobots that crawl.